The early-stage biotech Neuron23 and Qiagen (NYSE:QGEN) will work together to develop the first next-generation sequencing (NGS) companion diagnostic for Neuron23’s leucine-rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease NEU-723. In the collaboration, Qiagen will focus on developing and validating a clinical trial assay to detect biomarkers that predict the responsiveness of Parkinson’s disease…
Neuron23 names Kathy Dong to its board
The early-stage biotechnology firm Neuron23 has recruited the chief operating officer of Star Therapeutics, Kathy Dong, to join its board of directors. Founded in 2018, Neuron23 (South San Francisco) specializes in the discovery and development of drugs for neurodegenerative and immunological diseases, drawing insights from data science. Star Therapeutics (South San Francisco) focuses on the…
Neuron23 names chief medical officer
The early-stage biotech Neuron23 has appointed Dr. Sam Jackson as its first chief medical officer. South San Francisco, California–based Neuron23 specializes in developing precision medicines for genetically-defined neurological and immunological diseases. Jackson is a board-certified emergency physician with fellowship training in medical toxicology. “I am thrilled to welcome Dr. Jackson to our growing Neuron23 leadership…